Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Total Non-Current Liabilities: 2021-2024

Historic Total Non-Current Liabilities for SAB Biotherapeutics (SABS) over the last 4 years, with Dec 2024 value amounting to $11.8 million.

  • SAB Biotherapeutics' Total Non-Current Liabilities rose 24.83% to $16.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.0 million, marking a year-over-year increase of 24.83%. This contributed to the annual value of $11.8 million for FY2024, which is 20.39% down from last year.
  • Per SAB Biotherapeutics' latest filing, its Total Non-Current Liabilities stood at $11.8 million for FY2024, which was down 20.39% from $14.9 million recorded in FY2023.
  • In the past 5 years, SAB Biotherapeutics' Total Non-Current Liabilities registered a high of $31.9 million during FY2021, and its lowest value of $11.8 million during FY2024.
  • Its 3-year average for Total Non-Current Liabilities is $15.4 million, with a median of $14.9 million in 2023.
  • Data for SAB Biotherapeutics' Total Non-Current Liabilities shows a maximum YoY tumbled of 38.73% (in 2022) over the last 5 years.
  • Yearly analysis of 4 years shows SAB Biotherapeutics' Total Non-Current Liabilities stood at $31.9 million in 2021, then tumbled by 38.73% to $19.5 million in 2022, then dropped by 23.86% to $14.9 million in 2023, then dropped by 20.39% to $11.8 million in 2024.